Reports Q1 revenue $76,000, consensus $137,180. “The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position,” said Thijs Spoor, Perspective’s CEO. “Our focus on engineering the alpha advantage across every part of the radiopharmaceutical value chain – from the radioisotope to optimized structural chemistry, theranostic processes, and regional manufacturing – differentiates Perspective, and we look forward to providing clinical and manufacturing updates throughout 2026.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances
- Perspective Therapeutics Highlights Alpha-Targeted Oncology Strategy Update
- Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data
- Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET
- Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline